



DAFTAR PUSTAKA

- Al-Maskari, F., El-Sadig, M., dan Nagelkerke, N., 2010. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. *BMC Public Health*, **10**.
- Amalia, A., Andayani, T.M., dan Yuniarti, E., 2015. Hubungan Komplikasi Diabetes Melitus Terhadap Biaya Terapi. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **5**: 152–163.
- American Academy of Ophthalmology, 2014. *Retina and Vitreous Preferred Practice Pattern: Diabetic Retinopathy*. American Journal of Ophthalmology, USA.
- American Diabetes Association, 2010. Standards of Medical Care in Diabetes--2010. *Diabetes Care*, **33**: S11–S61.
- Andayani, 2013. *Farmakoekonomi: Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Australian Diabetes Society, 2008. Guidelines for The Management of Diabetic Retinopathy. *National Health and Medical Research Council*, **4176**: 44–47.
- Bootman, J.L., Townsend, R., dan McGhan, W., 2005. *Principles of Pharmacoeconomic*, 3rd edition. ed. Whitney Books Company, USA.
- Bourne, Rupert, R.A., Stevens, Gretchen, A., White, dan Richard, A., 2013. Causes of Vision Loss Worldwide, 1990 - 2010 : A Systematic Analysis. *The Lancet Global Health*, **1 (6)**: 339–349.
- Bressler, S.B., 2012. Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab. *Archives of Ophthalmology*, **130**: 1153.
- Charlson, Pompei P, Ales K.L, dan Mackenzie, 1987. A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation.
- Cheung, N., Mitchell, P., dan Wong TY, 2010. Diabetic Retinopathy. *Lancet*, **376 (9735)**: 124–126.
- Cheung, N., Wang, J.J., Klein, R., Couper, D.J., Sharrett, A.R., dan Wong, T.Y., 2007. Diabetic Retinopathy and the Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. *Diabetes Care*, **30**: 1742–1746.
- Colosia, A., Khan, S., dan Palencia, R., 2013. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 327.
- Dirani, M., Xie, J., Fenwick, E., Benarous, R., Rees, G., Wong, T.Y., dkk., 2011. Are Obesity and Anthropometry Risk Factors for Diabetic Retinopathy?: The Diabetes Management Project. *Investigative Ophthalmology & Visual Science*, **52**: 4416.



- Domeikienė, A., Vaivadaitė, J., Ivanauskienė, R., dan Padaiga, Ž., 2014. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. *Medicina*, **50**: 54–60.
- Duh, E.J., Sun, J.K., dan Stitt, A.W., 2017. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. *JCI Insight*, **2**: .
- Hletala, K., Harjutsalo, V., Forsblom, C., summanen, P., Groop, P.-H., dan on behalf of the FinnDiane study Group, 2010. Age at Onset and the Risk of Proliferative Retinopathy in Type 1 Diabetes. *Diabetes Care*, **33**: 1315–1319.
- Huang, Y.-Q., Gou, R., Diao, Y.-S., Yin, Q.-H., Fan, W.-X., Liang, Y.-P., dkk., 2014. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. *Journal of Zhejiang University SCIENCE B*, **15**: 58–66.
- Ilyas, H. dan Yulianti, S., 2008. *Ilmu Penyakit Mata*, 5th ed. Balai Penerbit FKUI, Jakarta.
- Javanbakht, M., Baradaran, H.R., Mashayekhi, A., Haghdoost, A.A., Khamseh, M.E., Kharazmi, E., dkk., 2011. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. *PLoS ONE*, **6**: e26864.
- Kanski, J., 2008. *Clinical Ophthalmology*. Butterworth Heinemann Elsevier, USA.
- Kasper, D., Fauci, A., Hauser, S., Longo, D., Lameson, J., dan Loscalzo, J., 2015. *Harrison's Principle of Internal Medicine, 19th Edition*. In *Harrison's Principles of Internal Medicine 19 Th Edition*, 19th edition. ed. McGraw - Hill Education, New York.
- Kim, T.H., Chun, K.H., Kim, H.J., Han, S.J., Kim, D.J., Kwak, J., dkk., 2012. Direct Medical Costs for Patients with Type 2 Diabetes and Related Complications: A Prospective Cohort Study Based on the Korean National Diabetes Program. *Journal of Korean Medical Science*, **27**: 876.
- Morsanutto, A., Berto, P., Lopatriello, S., Gelisio, R., Voinovich, D., Cippo, P.P., dkk., 2006. Major complications have an impact on total annual medical cost of diabetes. *Journal of Diabetes and its Complications*, **20**: 163–169.
- Romero-Aroca, P., de la Riva-Fernandez, S., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., Soler, N., dkk., 2016. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. *BMC Ophthalmology*, **16**: .
- Royal College of Ophthalmologists, 2012. *Diabetic Retinopathy Guidelines*. The Royal College of Ophthalmologists, London.
- Sanchez, L., 2005. *Pharmacoeconomics : Principles, Method and Application, Dalam : Pharmacotherapy A Pathophysiologic Approach*. McGraw - Hill Education, United States of America.
- Segel, J.E., 2006. Cost-of-illness studies—a primer. *RTI-UNC Center of Excellence in Health Promotion Economics*, 1–39.
- Shah, K., Gandhi, A., dan Natarajan, S., 2018. Diabetic retinopathy awareness and associations with multiple comorbidities: Insights from DIAMOND Study. *Indian journal of endocrinology and metabolism*, **22**: 30.



- Stefansson, E. dan Einarsdottir, A., 2015. Public Health and Prevention of Blindness in Diabetes. *International Journal of Diabetes Mellitus*, .
- Stratton, I.M., Kohner, E.M., Aldington, S.J., Turner, R.C., Holman, R.R., Manley, S.E., dkk., 2001. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia*, **44**: 156–163.
- Vaughan, D., Asbury, T., dan Eva, P., 2000. *Oftalmologi Umum*, 14th ed. Widya Medika, Jakarta.
- Viswanath, K. dan McGavin, M., 2003. Diabetic Retinopathy : Clinical Findings and Management Diabetic Retinopathy. *Community Eye Health*, , 16 (46) 21–24.
- Vogenberg, F., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw - Hill Education, United States of America.
- Walley, A., Haycox, A., dan Boland, A., 2004. *Pharmacoeconomics*. Elsevier Science Limited, Spain.
- 'WHO', , 2019. *WHO*. URL: <http://www.who.int/diabetes/en/> (diakses tanggal 13/5/2019).
- Wilkinson, C.P., Ferris, F.L., Klein, R.E., Lee, P.P., Agardh, C.D., Davis, M., dkk., 2003. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*, **110**: 1677–1682.
- Woodcock, A., Bradley, C., Plowright, R., ffytche, T., Kennedy-Martin, T., dan Hirsch, A., 2004. The influence of diabetic retinopathy on quality of life. *Patient Education and Counseling*, **53**: 365–383.
- Woung, L.-C., Tsai, C.-Y., Chou, H.-K., Tsai, M.-T., Tsai, W.-H., Chou, P., dkk., 2010. Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004. *BMC health services research*, **10**: 136.
- Zhang, X., Low, S., Kumari, N., Wang, J., Ang, K., Yeo, D., dkk., 2017. Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore. *PloS one*, **12**: e0180949.